ALS News Today

1st patient dosed in Phase 2 trial of SOD1-ALS treatment RAG-17

The first patient has been dosed in a Phase 2 clinical trial testing RAG-17 in people with ALS who carry mutations in the ...
MarketWatch

Ractigen Therapeutics Announces First Patient Dosed in Phase II Clinical Trial of RAG-17 for SOD1-ALS

The MarketWatch News Department was not involved in the creation of this content. NANTONG, China, Jan. 13, 2026 /PRNewswire/ -- Ractigen Therapeutics is pleased to announce that the first patient has ...
Seeking Alpha

Biogen Provides Update on FDA Advisory Committee Meeting on Tofersen for SOD1-ALS

CAMBRIDGE, Mass., March 22, 2023 (GLOBE NEWSWIRE) -- Biogen Inc. (BIIB) (Nasdaq: BIIB) announced today the outcome of the U.S. Food and Drug Administration’s (FDA) Peripheral and Central Nervous ...
Healio

European Commission authorizes Qalsody for SOD1-ALS

Please provide your email address to receive an email when new articles are posted on . The European Commission has granted marketing authorization under exceptional circumstances for Qalsody to treat ...
Healio

Tofersen improves functional independence in SOD-1 ALS

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Neurofilament light chain and cerebrospinal fluid ...
New York Post

Mother with rare ALS touts ‘miracle drug’ that has stopped her disease

Eight years after receiving a life-shattering diagnosis, a New Jersey mother credits an “amazing” new drug for stopping her disease in its tracks. Raziel Green, 52, an active runner and mother of two, ...
MarketWatch

Canadian HTA Assessments Recognize Therapeutic Value of QALSODY(TM) (tofersen injection) and its Potential to Modify Disease Progression in Individuals Living with SOD1-ALS

The MarketWatch News Department was not involved in the creation of this content. -- CDA issues positive reimbursement recommendation for QALSODY -- INESSS recognizes QALSODY's promising clinical ...
KHON2

AL-S Pharma Reports Positive Results from Phase 2 Study of AP-101 for the Treatment of ALS, Supporting Plans for a Confirmatory Phase 3 Study

ZURICH, Switzerland, Dec. 5, 2025 /PRNewswire/ -- AL-S Pharma, a clinical-stage biotech company dedicated to the development of AP-101 for the treatment of amyotrophic lateral sclerosis (ALS) today ...
Yahoo

AL-S takes mAb to Phase III after mid-stage ALS success

AL-S Pharma is planning a registrational study for its amyotrophic lateral sclerosis (ALS) monoclonal antibody (mAb), AP-101, after the drug met its efficacy and safety endpoints in a mid-stage trial.
Business Insider

The Journal of the American Medical Association (JAMA) Neurology Publishes Long Term Results from the QALSODY Phase 3 VALOR Study and its Open-Label Extension in SOD1-ALS

CAMBRIDGE, Mass., Dec. 22, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) – today announced that The Journal of the American Medical Association (JAMA) Neurology has published final results from ...
Morningstar

Ractigen Therapeutics Announces First Patient Dosed in Phase II Clinical Trial of RAG-17 for SOD1-ALS

NANTONG, China, Jan. 13, 2026 /PRNewswire/ -- Ractigen Therapeutics is pleased to announce that the first patient has been dosed in the Phase II clinical trial of RAG-17, an innovative siRNA therapy ...